BioPharm America™ 2013 Press Releases

April 18, 2013Return of BioPharm America™ 2013 to Boston will draw leading international life science dealmakers to Northeast EBD Group, the leading partnering firm for the life science industry, in collaboration with the Massachusetts Biotechnology Council (MassBio) announced today that BioPharm America™ 2013 will again be held in Boston September 17–19 at the Westin Boston Waterfront in Boston, MA. Senior executives from big pharma are set to attend, including AstraZeneca, Bayer HealthCare, EMD Serono...more ►

3 May 2013 China’s rapid growth nourishes biotech environment “Chinese investors haven’t lost a lot of money in biotech, so they’re in a good mood.” In the West, venture capital is drying up for life science firms so some small companies have come to Asia to raise financing where there is an available supply of money. more ►

18 March 2013 Elegant dysfunction in the push-pull of partnering Everything has changed in partnering on both sides of the table except the necessary tension for negotiating a good deal. Yet if the relations between VCs and pharma executives are strained, they still can't get enough of each other. more ►

18 March 2013 Should we fund technology or people in early stage innovation? Is the value in translational research and preclinical programs to be found in the science or the people who are carrying forward a potential breakthrough? Three executives on the front lines of investing offer surprising insights. more ►

18 March 2013 Stem cells: Do we need to wait 25 years for the Next Big Thing? With a Nobel Prize in 2012 and phenomenal potential for diagnostics and therapies, no one doubts that the next big thing will be stem cell derived products. In these (very) early days, this BIO-Europe Spring^® session presented current initiatives and challenges. more ►

18 March 2013 EU austerity puts pharma under “the tyranny of the urgent” Dramatic cost cutting in the five nations hardest hit by austerity measures is having "transmission effects" across the European Union with price cuts, reimbursement review and increasingly tender offers. more ►